- Home
- JNJ
as 05-16-2025 4:00pm EST
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 370.9B | IPO Year: | 1944 |
| Target Price: | $169.33 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 8.98 | EPS Growth: | -41.22 |
| 52 Week Low/High: | $140.68 - $169.99 | Next Earning Date: | 04-15-2025 |
| Revenue: | $89,331,000,000 | Revenue Growth: | 4.30% |
| Revenue Growth (this year): | 3.87% | Revenue Growth (next year): | 4.15% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decker Robert J | JNJ | VP Corporate Controller | Feb 25 '25 | Sell | $165.88 | 6,999 | $1,160,994.12 | 21,001 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?
Business Wire
4 days ago
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
TipRanks
4 days ago
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance
Motley Fool
5 days ago
The Smartest Dividend Stocks to Buy With $5,000 Right Now
Insider Monkey
5 days ago
Is Johnson & Johnson (JNJ) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?
Barrons.com
5 days ago
Big Pharma Counted on This Loophole. It May Be Closing.
Investor's Business Daily
5 days ago
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
MT Newswires
5 days ago
Leerink Partners Downgrades Johnson & Johnson to Market Perform From Outperform, $153 Price Target
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.